You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020156016
Dec 20202907
Jan 20212809
Feb 20212406
Mar 202164011
Apr 202142011
May 20211409
Jun 2021007
Jul 20210017
Aug 2021008
Sep 20210026
Oct 202140032
Nov 202140016
Dec 20211405
Jan 20223202
Feb 20223806
Mar 20222606
Apr 202258010
May 20225405
Jun 20223400
Jul 20221602
Aug 20224206
Sep 20222002
Oct 202224012
Nov 20223006
Dec 20224806
Jan 20233205
Feb 20232004
Mar 20234808
Apr 202340010
May 20234606
Jun 20233602
Jul 20232203
Aug 20232804
Sep 20233402
Oct 20233605
Nov 20236404
Dec 20233400
Jan 20243400
Feb 20243401
Mar 20244800
Apr 20242001
May 20243801
Jun 20244201
Jul 20243802
Aug 20243404
Sep 20244401
Oct 20242603
Nov 20243403
Dec 20243802
Jan 20255607
Feb 20251405
Mar 2025003
Apr 2025002
May 2025005
Jun 2025003
Total18130340